Detalles de la búsqueda
1.
Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma.
Ann Hematol
; 90(12): 1449-56, 2011 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-21437586
2.
ThaDD plus high dose therapy and autologous stem cell transplantation does not appear superior to ThaDD plus maintenance in elderly patients with de novo multiple myeloma.
Eur J Haematol
; 84(6): 474-83, 2010 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-20331733
3.
Thalidomide-dexamethasone versus interferon-alpha-dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised study.
Br J Haematol
; 144(5): 653-9, 2009 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-19036082
4.
Serum C-reactive protein at diagnosis and response to therapy is the most powerful factor predicting outcome of multiple myeloma treated with thalidomide/ anthracycline-based therapy.
Clin Lymphoma Myeloma
; 8(5): 294-9, 2008 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-18854284
5.
Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma.
Leuk Lymphoma
; 53(9): 1722-7, 2012 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-22335534
6.
Assessment of vulnerability measures and their effect on survival in a real-life population of multiple myeloma patients registered at Marche Region Multiple Myeloma Registry.
Clin Lymphoma Myeloma Leuk
; 12(6): 423-32, 2012 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-22981966
7.
Infectious complications in patients with multiple myeloma treated with new drug combinations containing thalidomide.
Leuk Lymphoma
; 52(5): 776-85, 2011 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-21338282
8.
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.
J Clin Oncol
; 29(8): 986-93, 2011 Mar 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-21282540
9.
Outcome and toxicity in the modern era of new drugs for multiple myeloma: a reappraisal for comparison with future investigational trials.
Clin Lymphoma Myeloma Leuk
; 10(5): 353-60, 2010 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-21030348
10.
Melphalan, prednisone, and thalidomide versus thalidomide, dexamethasone, and pegylated liposomal doxorubicin regimen in very elderly patients with multiple myeloma: a case-match study.
Leuk Lymphoma
; 51(8): 1444-9, 2010 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-20496998
11.
Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma.
Eur J Haematol
; 78(4): 297-302, 2007 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-17286608
12.
Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma.
Blood
; 108(7): 2159-64, 2006 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-16763209
Resultados
1 -
12
de 12
1
Próxima >
>>